Is Mounjaro Available in Public or Private Care?

Mounjaro can no longer be treated as a question of whether the medicine exists in Singapore at all. HSA’s newer drug-approval notices show tirzepatide is registered locally and indicated for both type 2 diabetes mellitus and weight management in specified adults, while remaining a prescription-only medicine. The more practical question is where it is actually prescribed, how the care pathway differs between sectors, and whether access is subsidised. To explore more about the broader prescribing pathway, see How Mounjaro Is Prescribed in Singapore: Clinics, Telehealth, and Medical Requirements.

In Singapore, the most accurate framing is that Mounjaro may sit within both public and private medical care, but availability is not identical across all settings. MOH states that drug subsidies apply at public hospitals, specialist outpatient clinics, and polyclinics, and also notes that drug availability varies by healthcare institution depending on the conditions commonly managed there and the drugs usually prescribed by its doctors. As of MOH’s subsidised-drug list dated 1 April 2026, neither “tirzepatide” nor “Mounjaro” appears on that list.

Key Takeaways

• Mounjaro is registered in Singapore and listed by HSA as a prescription-only medicine.

• HSA’s 2025 approval notices show local indications for type 2 diabetes mellitus and weight management in specified adults.

• Public-sector obesity and diabetes services do exist in Singapore, including hospital-based programmes that use pharmacotherapy as part of care.

• Access in public care is not the same as guaranteed routine supply at every institution. MOH says drug availability varies by institution.

• As of 1 April 2026, Mounjaro does not appear on MOH’s subsidised-drug list, so patients should not assume it is subsidised in public care.

• In private care, prescribing is still a doctor-supervised medical decision, not a retail purchase. This is an inference from HSA’s prescription-only classification and MOH’s outpatient-medical-services framework.

The short answer: potentially both, but not in the same way

The cleanest answer is that Mounjaro may be encountered through both public and private care pathways, but patients should not assume the process is identical. Public care is shaped by hospital or specialist-clinic services, institutional formularies, and subsidy rules. Private care may be more direct operationally, but it still requires a doctor’s assessment because tirzepatide is not an over-the-counter medicine.

So the issue is less “public versus private” in theory, and more which institution, for what indication, and under what follow-up arrangement.

What the public-care pathway can look like

Singapore’s public sector clearly has structured obesity and metabolic services. SGH’s Obesity Centre describes itself as a hospital-based centre providing evidence-based treatment for obesity and related conditions, and its clinical-services page states that pharmacotherapy is one treatment modality used by endocrinologists for obesity management. KTPH’s Integrated Care for Obesity & Diabetes service likewise describes a multidisciplinary clinic involving weight-management physicians, endocrinologists, dietitians, physiotherapists, psychologists, and surgeons.

That means the public sector does have places where a medicine like Mounjaro could be considered within supervised obesity or diabetes care. But that is not the same as saying every public hospital, every specialist clinic, or every polyclinic routinely prescribes or stocks it. MOH explicitly says drug availability varies by institution.

What “available in public care” does not necessarily mean

Patients often hear that a medicine is available in Singapore and assume that it must therefore be widely accessible through subsidised public channels. That is not always how the system works.

MOH’s subsidised-drug page makes two points that matter here: subsidies apply in public institutions, and actual drug availability varies by institution. On the same page set, as of 1 April 2026, “tirzepatide” and “Mounjaro” do not appear in the subsidised-drug list search results. That does not prove no public doctor can prescribe it, but it does mean patients should not assume standard subsidy coverage.

What private care usually means in this context

In private care, the path is often operationally simpler: the patient consults a doctor, the doctor assesses suitability, and prescribing can proceed if clinically appropriate and supply is available. But the medical standard does not become lower just because the setting is private.

HSA’s approval notices and benefit-risk framework make clear that Mounjaro is a regulated therapeutic product, and its latest approval notices list it as a P-classified registered medicine with specified indications. That means private-sector access should still be understood as prescription access under medical supervision, not consumer purchase on request.

Why the indication matters

Another reason public-versus-private questions can become confusing is that Mounjaro’s local position has changed over time. HSA’s older March 2023 approval notice focused on type 2 diabetes, while HSA’s June 2025 and October 2025 drug-approval notices list both the diabetes indication and a weight-management indication for adults meeting specified BMI criteria and, where relevant, weight-related comorbidity criteria.

That means current discussions about access should be based on the newer HSA approvals, not older Singapore articles written before the later indication expansion.

Public care may be more pathway-driven

Public-sector prescribing is often tied to specialist workflows. A patient may first be seen through endocrinology, obesity, or diabetes services, and medication may be considered alongside dietitian input, activity planning, and review of metabolic risk rather than as a single-request prescription. SGH and KTPH both describe multidisciplinary models rather than medicine-only access.

For that reason, public access may feel more structured and less transactional. That can be useful for safety and continuity, but it may also mean the medicine is introduced only when it fits the institution’s clinical pathway and formulary practice. This last point is an inference from MOH’s statement that drug availability varies by institution.

Private care may be more direct, but not automatic

Private clinics may offer a faster consultation pathway, including telehealth-supported follow-up in some cases. But that still does not make Mounjaro an automatic option.

Singapore’s remote and outpatient care framework expects proper clinical assessment and safe prescribing, and HSA continues to classify Mounjaro as prescription-only. So even in private care, the relevant question remains whether the patient is medically suitable, can be monitored properly, and fits the approved or otherwise clinically justified pathway the doctor is using.

The subsidy question matters more than many patients expect

For many patients, the real distinction between public and private care is not just where the consultation happens. It is whether the medicine is subsidised.

On current MOH information, public institutions have drug-subsidy frameworks, but Mounjaro does not appear in the subsidised-drug list as of 1 April 2026. MOH also states that each institution’s actual drug availability varies. Put together, that suggests patients should ask two separate questions: “Can this institution prescribe it?” and “Is it subsidised here?” rather than assuming the answer to both is yes.

A practical way to answer the question

A clinically careful answer is this: yes, Mounjaro may be encountered in both public and private care in Singapore, but access is uneven and subsidy should not be assumed. Public hospitals clearly have obesity and diabetes services that use pharmacotherapy, while private care may provide a more direct route to doctor assessment. Yet because Mounjaro is a regulated prescription medicine, both sectors still depend on medical judgement, institutional practice, and follow-up capacity.

Takeaway

Mounjaro is available in Singapore as an HSA-registered, prescription-only medicine, and current HSA approvals cover both type 2 diabetes and weight management in specified adults. In practical terms, it may be discussed in both public and private care, but availability is not uniform across institutions. Public hospitals do have obesity and metabolic clinics that use pharmacotherapy, yet MOH states that drug availability varies by institution, and Mounjaro does not appear on the MOH subsidised-drug list as of 1 April 2026.

So the most accurate patient-facing message is not simply “public” or “private.” It is that access depends on the institution, the indication, the doctor’s assessment, and whether the medicine is stocked or subsidised in that setting.

FAQ

Is Mounjaro approved in Singapore?

Yes. HSA’s 2025 drug-approval notices list Mounjaro as approved in Singapore, with indications covering type 2 diabetes mellitus and weight management in specified adults.

Is Mounjaro prescription-only in Singapore?

Yes. HSA lists Mounjaro as a prescription-only registered medicine.

Can public hospitals manage obesity with medication?

Yes. SGH’s Obesity Centre states that pharmacotherapy is one of its obesity-management modalities, and KTPH describes a multidisciplinary obesity-and-diabetes service.

Does public-sector availability mean the drug is subsidised?

Not necessarily. MOH says drug subsidies exist in public institutions, but actual drug availability varies by institution, and Mounjaro does not appear on the subsidised-drug list as of 1 April 2026.

Is private care the only place to get Mounjaro?

The official sources do not support reducing the answer to that. A better reading is that both sectors may be relevant, but access depends on institutional practice, prescribing assessment, and supply rather than a simple public-versus-private rule.